Mireca’s key patent application receives “Notice ofAllowance” from USPTO

20.02.2019 Mireca’s key patent application receives “Notice ofAllowance” from USPTO

Mireca Medicines GmbH, anophthalmology start-up company developing treatments for inherited retinaldegeneration, receives the validating “Notice of Allowance” from the USPTO for its proprietary formulation and medical use patent application “Targeted liposomal delivery of cGMP analogues” (PCT/EP2016/055659).

German ophthalmology start-up Mireca Medicines GmbH receives “Notice of Allowance” for its patent application “Targeted liposomal delivery of cGMP analogues” (PCT/EP2016/055659) from the United States Patent and Trademark Office (USPTO), declaring that the application has been examined and is allowed for issuance as a patent.

The invention relates to means and methods for targeted drug delivery of cGMP analogues for retinal and other diseases. All inventors are related to the group of founders and shareholders of Mireca, which wholly owns this patent. Mireca’s lead program of developing LP-DF003, a liposomal cGMP analogue formulation, inRetinitis Pigmentosa (RP), Leber’s congenital amaurosis (LCA) and Stargardt’s disease(STGD) is a first application of this patent. Further benefits and protection for this development program comes from our orphan drug designation (ODD) in the lead indication (EU/3/15/1462). Also wholly owned patent applications “PKG antagonists”(PCT/EP2017/066113) and “PKG agonists” (PCT/EP2017/071859), both protecting the routes of manufacturing +250 further cGMP analogues as composition of matter, provide for an extension of the cGMP approach into other, more common neurodegenerative retinal diseases like age-related macular degeneration and diabetic retinopathy, as well as other disease indications.

“Being rewarded with an issued US patent for the core of our invention is very rewarding and a validation of Mireca’s set of intellectual property, manufacturing and (pre)-clinical assets”, comments Prof. Dr. François Paquet-Durand, CSO of Mireca. “Allowance of Mireca’s first patent application crucially supports our current fundraising, aimed at driving forward clinical development of LP-DF003 in the near future”, adds Barbara Brunnhuber, CEO of Mireca Medicines GmbH.

Source: https://static1.squarespace.com/static/5aa00bfe7e3c3a495cd9c440/t/5c6d2c5b53450a9d916f2a06/1550658652409/2019+02+20+Mireca%27s+key+patent+application+receives+Notice+of+Allowance+from+USPTO.pdf

For further information, please contact

Mireca Medicines GmbH
Barbara Brunnhuber, CEO
Phone: +31 6 23 93 69 66
E-mail: bb [at] mireca.eu